Jeannette Y. Wick, RPh, MBA, FASCP

Articles by Jeannette Y. Wick, RPh, MBA, FASCP

Antithrombotic therapy is an essential element of treatment after patients experience acute coronary syndrome. Fortunately, prescribers can draw from a considerably larger selection of antithrombotics than ever before, as prasugrel, ticagrelor, fondaparinux, and bivalirudin have joined warfarin, unfractionated heparin, and the low molecular weight heparins in evidence-based guidelines.